NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF
THE PRESENT INVENTION RELATES TO 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-(3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE, ITS SOL-VATES AND CRYSTALLINE MODIFICATIONS THEREOF. THE PRESENT INVENTION FURTHER RELATES TO PROCESSES OF MANUFACTURING THESE CRYSTALLINE MODIFICATIONS AS WELL AS THEIR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS, WHICH ARE CAUSED, MEDIATED AND/OR PROPAGATED BY THE INHIBITION, REGULATION AND/OR MODULATION OF SIGNAL TRANSDUCTION OF KINASES, IN PARTICULAR BY THE INHIBITION OF TYROSINE KINASES, E.G. PATHOPHYSIOLOGICAL CONDITIONS SUCH AS CANCER.
